Dalteparin in combination with abciximab during percutaneous coronary intervention

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Pharmacology

Background:

• Established efficacy of dalteparin and abciximab individually for non-ST-segment elevation acute coronary syndromes.
• Lack of established guidelines for combining these antithrombotic agents.
• Need to evaluate safety and efficacy of combined dalteparin and abciximab regimens during percutaneous coronary intervention (PCI).

Purpose of the Study:

• To assess the anticoagulant effect of various dalteparin dosing regimens.
• To evaluate the clinical safety of dalteparin when used with abciximab during PCI.
• To determine optimal dalteparin dosage for combination therapy in PCI procedures.

Main Methods:

• Patients undergoing PCI with abciximab received varying dalteparin regimens.
• Subcutaneous (SQ) dalteparin administered prior to PCI, with intravenous (IV) doses based on timing.
• Randomized IV dalteparin at 40 IU/kg or 60 IU/kg during PCI for patients without prior therapy or >12 hours post-SQ dose.

Main Results:

• The 60 IU/kg IV dalteparin group showed a significantly lower incidence of procedural thrombosis (0% vs. 11.1%, P <.01).
• Consistent antithrombotic effect (anti-factor Xa activity) was observed with the 60 IU/kg dose.
• Both 40 IU/kg and 60 IU/kg IV dalteparin groups exhibited similar rates of major bleeding (3.7% vs. 2.6%).

Conclusions:

• Intravenous dalteparin at 60 IU/kg is safe and effective when co-administered with abciximab during PCI.
• This specific regimen offers improved procedural thrombosis prevention in acute coronary syndrome patients undergoing PCI.
• The findings support the use of this dalteparin dosage in combination therapy for PCI.